BRIEF-Puma Biotechnology Reports Q4 Loss Per Share $0.38
BRIEF-Puma Biotechnology Reports Q4 Loss Per Share $0.38
* PUMA BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
* Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.14
* Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA
* Q4 LOSS PER SHARE $0.38
* Q4 REVENUE $52.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $52.8 MILLION
* NET NERLYNX REVENUE IN Q4 OF 2020 WAS $50.0 MILLION, VERSUS $58.7 MILLION IN Q4 OF 2019
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
Feb 25 (Reuters) - Puma Biotechnology Inc :
* PUMA BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
* Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.14
* Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA
* Q4 LOSS PER SHARE $0.38
* Q4 REVENUE $52.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $52.8 MILLION
* NET NERLYNX REVENUE IN Q4 OF 2020 WAS $50.0 MILLION, VERSUS $58.7 MILLION IN Q4 OF 2019
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透2月25日電-彪馬生物技術公司(Puma Biotechnology Inc)：*PUMA生物技術報告第四季度和全年財務業績*第四季度調整後非GAAP每股虧損0.14美元*第四季度每股收益預估$-0.29-REFINITIV IBES數據*第四季度每股虧損0.38美元*第四季度收入為5260萬美元，而REFINITIV IBES估計為5280萬美元*2020年第四季度NERLYNX淨收入為5000萬美元，而2019年第四季度為5870萬美元Eikon的源文本：進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧